February 7 - 9, 2018 - 7th Conference of the European Hidradenitis Suppurativa Foundation, Rotterdam, The Netherlands
Efficacy data on IFX-1 from the Phase 2a study in patients with severe Hidradenitis Suppurativa, not eligible for biological treatment or primary or secondary failure of biological treatment, have been accepted for oral presentation.
Evangelos J. Giamarellos-Bourboulis, MD, PhD (ATTIKON University Hospital, Athens, Greece)
Thursday, Feb 8, 2018
1:50pm – 2:50pm CET
The abstract #EHSF2018.51 will be available from February 7 at www.ehsf2018.com.